Fig. 2From: Trends in overall mortality among US veterans with primary myelofibrosisOverall Survival of Patients in Pre- and Post-Ruxolitinib Approval Groups in the A Overall Population, and B With < 2 Modified IPSS Risk Factors. HR, hazard ratio; IPSS, International Prognostic Scoring System; RUX, ruxolitinibBack to article page